House Energy and Commerce/Oversight Subcommittee Chairman Dingell (D-Mich.) formally requests firm to "furnish copies of all Establishment Inspection Reports and Form 483 Reports covering FDA inspections of all Abbott Laboratories' pharmaceutical manufacturing facilities since Jan. 1, 1985." The request follows 41-page FD-483 resulting from FDA inspection of the company's injectable drug facility in North Chicago. Abbott has until Dec. 22 to respond to subcommittee.
You may also be interested in...
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.
Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.